The FDA cleared IceCure Medical's XSense Cryoablation System for general minimally invasive cryoablation.

The US FDA has granted regulatory clearance to IceCure Medical's XSense Cryoablation System for general minimally invasive cryoablation across various specialties. The system uses extreme cold temperatures to destroy tissue and treats conditions like fibroadenomas, kidney tissue, liver metastases, tumors, skin lesions, and warts. Clearance validates the platform cryoablation technology's safety and efficacy, also granted for the same indications as the company's flagship ProSense system.

July 01, 2024
5 Articles

Further Reading